Levi & Korsinsky, LLP announces that it has commenced an investigation of Neos Therapeutics, Inc. (“Neos Therapeutics” or the “Company”) (NASDAQGM: NEOS) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
On October 19, 2015, Neos Therapeutics disclosed that the U.S. Food and Drug Administration has identified deficiencies in the Company’s new drug application for Cotempla XR-ODT that preclude discussion of labeling and marketing requirements at this time. Shares of Neos Therapeutics were down more than 23% on intraday trading on October 20, 2015. Then on August 11, 2016, Neos announced its financial results for the second quarter of 2016, reporting it had missed its earnings expectations by a significant $0.49 per share. Following this news, shares of Neos fell from a close of $8.57 per share on August 10, 2016 to a close of $7.27 per share on August 11, 2016.
To receive more information, please fill out the form.